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ABSTRACT
Kaposi Sarcoma (KS) is themost commonAIDS-defining cancer, even
as HIV-positive people live longer. Like other herpesviruses, human
herpesvirus-8 (HHV-8) establishes a lifelong infection of the host that
in association with HIV infection may develop at any time during the
illness. With the increasing global incidence of KS, there is an urgent
need of designing optimal therapeutic strategies for HHV-8-related
infections. Here we formulate two models with innate and adaptive
immune mechanisms, relevant for non-AIDS KS (NAKS) and AIDS-KS,
where the initial condition of the secondmodel is given by the equi-
librium state of the first one. For the model with innate mechanism
(MIM), we define an infectivity resistance threshold that will deter-
mine whether the primary HHV-8 infection of B-cells will progress to
secondary infection of progenitor cells, a concept relevant for viral
carriers in the asymptomatic phase. The optimal control strategy has
been employed to obtain treatment efficacy in case of a combined
antiretroviral therapy (cART). For the MIM we have shown that KS
therapy alone is capable of reducing the HHV-8 load. In the model
with adaptive mechanism (MAM), we show that if cART is adminis-
tered at optimal levels, that is, 0.48 for protease inhibitors, 0.79 for
reverse transcriptase inhibitors and 0.25 for KS therapy, both HIV-1
and HHV-8 can be reduced. The predictions of these mathemati-
cal models have the potential to offer more effective therapeutic
interventions in the treatment of NAKS and AIDS-KS.
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The African region remains to be the most affected, accounting for two-third of the peo-
ple livingwithHIVworldwide (https://www.who.int/gho/hiv/en/). AlthoughHIV-positive
people who start antiretroviral therapy (HAART) have the same life expectancy as their
HIV negative peers, they develop co-morbidities on average 16 years earlier thanHIV neg-
ative people (http://www.natap.org/2020/CROI/croi_134). KS is one of the most common
malignancies causing co-morbidity in patients with human immunodeficiency virus-1
(HIV-1) infection, especially at the later HIV stage (AIDS). Most of AIDS-related cancers
are caused by oncogenic viruses such as Epstein Barr virus (EBV), human herpesvirus 8
(HHV-8) and Human papillomavirus (HPV) [7].
There are four different forms of KS: Classic or sporadic KS, African or Endemic KS,
AIDS-associated or epidemic KS and Transplant or Immunosuppression-associated or
Iatrogenic KS [13]. The development of each of these forms is dependent on prior infec-
tion with HHV-8. However, HHV-8 infection alone is insufficient for the development of
KS and some form of immunodeficiency is necessary for disease progression [31].
Most individuals infected with African KS and Classic KS but with strong immune
responses have remained latently infected with HHV-8 throughout their lifetime [13,14]
The co-factors involved in the development of Classic and Endemic KS are not fully under-
stood although environmental and genetic factors such as age, sex, malnutrition and so on
have been implicated [13]. Progression from HHV-8 infection to KS is a complex process.
For instance, not everyAIDSpatient developsKS even in the face of profound immunosup-
pression, only a minority of HHV-8-infected transplant recipients develop iatrogenic KS,
and that people with Classic or Endemic KS are not typically immunosuppressed [17,20].
Whether HHV-8 infection develops into an asymptomatic or symptomatic KS, depends
on the interplay between HHV-8 and the host immune system. When HHV-8 infec-
tion occurs, the immune system promotes an environment where cellular proliferation,
cell migration, angiogenesis and cytokine/chemokine production are enhanced [13]. The
immune response occurs in two stages: first by triggering the innate response and second,
if the infection persists, the adaptive response [30]. A review by Foreman et al. [13] has
suggested how infection of progenitor cells by HHV-8 can initiate the development of all
forms of KS. For individuals dually infected with both HIV-1 and HHV-8, the HHV-8
infection is enhanced by the HIV-1 growth factors which stimulate both uninfected and
infected B-cells to proliferate in response to T-cell signals [13]. The T-cell signals stimulate
the latently infected B cells. These cells that were dormant are now capable to proliferate
and increase the population of HHV-8 producing cells.
With regard to mitigating the spread of the disease, especially in the case for childhood
diseases and malaria, preventive measures are given priority over treatment. Current pro-
tocol advises individuals going to malaria endemic areas to take malaria prophylaxis drugs
1 week before departure to prepare their immune system to fight and clear the infection
before it develops into active disease. In this study, our objective is to demonstrate how
administration of HAART to individuals co-infected with HIV-1 and HHV-8 can prevent
the occurrence of KS by ensuring lowHIV-1 viremiawhich prevents reactivation of latently
infected B cells [13].
When a pathogen invades the body, the body triggers an innate, non-specific immune
response to clear the infection. This response consists of cellular (immune cells) and chem-
ical (e.g. cytokines) defenses to reduce the growth of the population of infected cells and
to eliminate the pathogens. The innate immune response may be viewed as a way to
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Figure 1. Schematic diagram of the MIM describing interactions for NAKS.
suppress and control HHV-8 infection before the adaptive immune response character-
ized by the clonal expansion of lymphocytes is activated. Using mathematical modelling,
we show that a dynamic motif in Figure 1 comprising of interactions between infected B
cells, infected progenitor cells, KS cells, HHV-8 virions and the innate immune response, is
able to prevent a potentially NAKS fromdeveloping into a clinical disease. This has twofold
implications. First, key innate immune signallingmolecules induced by viral infection lead
to the production of a broad range of antiviral proteins and cytokines. Uncontrolled release
of these cytokines can lead to cytokine storm, causing tissue damage or indirectly causing
pathology even before the initiation of HAART [23]. Second, antibody test can detect HIV
infection as early as 1–2 weeks after exposure and testing after 2 or 3 weeks is not very use-
ful (http://i-base.info/guides/testing/what-is-the-window-period). Hence, it is essential to
understand at what level to deem the innate immune response or cytokine therapy to be
safe.
If the infection progresses despite the innate response, the immune system mounts a
more robust, longer lasting adaptive or acquired immune response. Hence, we construct
a second model that mimics the body’s adaptive immune response by including the inter-
actions as in Figure 4 between HIV-1 virions, HIV-1- and HHV-8-specific effector cells,
infected CD4 T cells, uninfected B- and CD4 T cells. The initial condition ofMAMl will be
determined by the equilibrium states of the MIM, assuming an advanced stage of HIV-1
and HHV-8 co-infection. Importantly, we find an infectivity threshold that will be criti-
cal for the primary HHV-8 infection to develop into an advanced KS. To determine the
drug efficacy level of HAART alone or combined HAART and chemotherapy, we will
take an optimal control approach. This is motivated by the fact that HAART should be
the first step therapy in optimal control of HIV infection for AIDS-KS. However, patients
with high-risk KS rarely respond to HAART alone and hence, chemotherapy is recom-
mended which requires balancing the immunosuppressive effects of chemotherapy with
its potential benefit.
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To develop these models, we shall apply the Foreman et al. [13] approach. According to
this hypothesis, AIDS-KS arises from the erroneous infection of progenitor cells by HHV-
8 which is enhanced by action of HIV-1 infected host cells. These HIV-1 infected cells
produce cytokines and growth factors that stimulate the progenitors of the KS cells which
makes them susceptible to HHV-8 infection. In summary, we will show that early HHV-8-
specific intervention is important as it can control the HHV-8 infection from developing
into a progressive KS. We also determine efficacy levels for cART therapy at which HIV-
1 and HHV-8 co-infection can be kept under control, thus providing valuable testable
predictions for clinical researchers.
2. Model with innatemechanism (MIM)
2.1. Model formulation and description
We formulate amodel based on Foreman et al. [13] representing two subsystems as follows:
the first subsystem representing the primary infection of B cells leading to the production
of HHV-8 and the second subsystem representing the erroneous infection of progenitor
cells leading to the development of KS.
The MIM includes infected B-cells, X1(t), HHV-8 virions, X2(t), infected progenitor
cells,X3(t), KS cells,X4(t), and the innate immune response,X5(t). The interaction among













Equation (1) describes the dynamics of the infected B cells, X1. This class is assumed to
grow logistically but regulated by the efficacy threshold of the innate immune response.
The dependence on X1 itself rather than the HHV-8 load is plausible, since no correlation
has been observed between the B-cell subsets and the HHV-8 viremia [6]. The last term
accounts for natural death of infected B cells at a constant rate μx1 .
Ẋ2(t) = Nx2μx1X1 − μx2X2. (2)
Equation (2) represents the dynamics of HHV-8, X2. The first term represents the produc-
tion of these virions from the bursting of infected B cells, whereNx2 is the carrying capacity
or maximum number of virions that can be contained within an infected B cell. The last












Equation (3) describes the dynamics of the infected progenitor cells, X3. The first term
represents a source term which grows logistically with respect to the viral level, X2, and
moderated by the innate immune response, X5. The effect of the innate immune response,
X5, is moderated by the saturation parameter, θx5 , which is significant in this study as it
mimics how administration of vaccines or drugs can alter the progression of the infec-
tion [19]. The logistic growth term is expressed in terms of HHV-8 viremia to emphasize
JOURNAL OF BIOLOGICAL DYNAMICS 217
that progenitor cells and in general stem cells proliferate in response to infectious stimuli
[3,5,8,15,19,24,27]. This formulation can assist to make decisions on viral load depen-
dent intervention measures depending on the viremia reservoir levels. The second term
represents the blanket death of these cells at a constant rate, μx3 .
Ẋ4(t) = μ̂x3X3 − μx4X4. (4)
Equation (4) represents the concentration of KS, X4. The first term designates the growth
of KS, as the infected progenitor cells transform into cancerous cells, at a constant rate,
μ̂x3 < μx3 . It is assumed that μ̂x3 < μx3 as not all infected progenitor cells progress to KS
[13]. The second term is natural death of KS at a constant rate μx4 .
Ẋ5(t) = K3 X1
θx1 + X1
− K3X5 (5)
Equation (5) represents the innate immune response,X5. The first term represents the stim-
ulation of the innate immunity due to the presence of infected B cells,X1. It is assumed that
X5 is stimulated by the infected B cells,X1, in a saturable manner with the scaling constant,
θx1 , and decays at a constant rate K3 [4]. The model (1)–(5) is developed to demonstrate
how infection errors committed byHHV-8 by erroneously infecting progenitor cells lead to
a more serious problem of KS. This model can then be used to demonstrate that externally
administered drugs or immune boosters can alter the infection and stop the development
of KS.
2.2. Analysis of themodel
2.2.1. Positivity and boundedness of solutions
We denote by R5+ the set of points Xt = (X1(t),X2(t),X3(t),X4(t),X5(t)) in R5 with
positive coordinates and consider the system (1)–(5) with initial values
X0 = (X01,X02,X03,X04,X05) ∈ R5+.
In this section, we prove the following theorem.
Theorem 2.1: If X0i ≥ 0, then Xi(t) ≥ 0 for all t > 0, i = 1, . . . , 5.
Before we prove Theorem 2.1, we rearrange the system into a subsystem of infected
progenitor and infected B cells,W = (X1(t),X3(t))T , written in matrix form as




























, j ∈ {1, 2},
r(X5) = 1 − X5
θx5 + X5
, Q = r(X5)KF,
Fj(Xj) = Xjfj(Xj) is the jth entry of the vector, F, j = 1, 2
(7)
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Let Qj denote the jth entry of Q, j = 1, 2, where Qj represents the jth source term in (6)
and r(X5) measures the efficacy of the innate immune response. Define a subsystem con-
sisting of HHV-8 and KS, Y = (Y2(t),Y4(t))T = (X2(t),X4(t))T , which can be expressed
in matrix form as

















The proof is done in three steps: First, we prove that the source terms in (6) are nonneg-
ative, i.e. Q := r(X5)KF ≥ 0. Second, we want to show that Xi(t) ≥ 0, i = 1, 3, t > 0 and
finally, we conclude that Yi(t) ≥ 0 for t > 0, i = 2, 4.
Proof: From Equation (5), we can deduce that X5(t) ≥ X5(0) exp(−K3t) ≥ 0. Notice that
r(X5) = 1 − X5θx5+X5 =
θx5
θx5+X5 > 0, for θx5 > 0.
The function Fj(Xj) in (7) has zeros at Xj = 0 and Xj = xjmax , has a peak at Xj = xjmax2
and is positive in the interval 0 < Xj < xjmax . Since K ≥ 0, we have Qj ≥ 0, j = 1, 2.
The matrix Mw in (6) is a Mertzler matrix and fj(Xj) ≥ 0, the solution of (6) is non-
negative for all t > 0. The matrix E ≥ 0 since Xi ≥ 0 for i = 1, 3. The matrix My is a
Mertzler matrix and hence, the solution of (8) is nonnegative for t > 0.We conclude that if
X0i ≥ 0, i = 1, 2, 3, 4, 5, then the solution Xi(t), of the system (1)–(5) remains in R5+. 
2.3. Steady states and the basic reproduction number
The virus free equilibrium of the MIM given by Equations (1)–(5) is ε0 = (X01,X02,X03,X04,
X05) = (0, 0, 0, 0, 0). In what follows, we will calculate the basic reproduction number of
the system (1)–(5) using the next generation operator method [9]. The basic reproduction
number is determined by the number of newly infected B cells. Using this approach, we











where X ∈ R,Y ∈ R and Z ∈ R3, and h(X, 0, 0) = 0. Assuming that the equation
g(X∗,Y,Z) = 0 implicitly determines a function Y = g̃(X∗,Z). We let A = DZh(X∗,
g̃(X∗, 0), 0) and further assume that A can be written in the form A = C − D, with C ≥ 0
(that ismij ≥ 0) andD ≥ 0 is a diagonal M-matrix.
In system (9), X denotes the innate immune response, Y represents the HHV-8 virions
and the components of Z represent the HHV-8-associated cells, i.e. X = X5,Y = X2,Z =
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(X1,X3,X4). Let U0 = (X∗, 0, 0) denote the virus free equilibrium, that is,




and D = diag (μx1 ,μx3 ,μx4) .
We compute A = DZh(X∗, g̃(X∗, 0), 0) and get
C =
⎛
⎜⎝ K2 0 0K1Nx2μx1μx2 0 0
0 μ̂x3 0
⎞

















2.4. Local stability of the virus free equilibrium, ε0
Lemma 2.1: The virus free equilibrium point ε0 is locally asymptotically stable ifR0 < 1.
Proof: We consider the Jacobian matrix of the system (1)–(5), evaluated at the virus free




K2 − μx1 0 0 0 0
Nx2μx1 −μx2 0 0 0
0 K1 −μx3 0 0






We note that J(ε0) is a lower triangular matrix. Hence, the corresponding eigenvalues are
the entries in the main diagonal. In other words,
λ1 = K2 − μx1 , λ2 = −μx2 , λ3 = −μx3 , λ4 = −μx4 , λ5 = −K3.
For local stability of ε0, λ1 = K2 − μx1 = μx1(R0 − 1) < 0. Hence, all the eigenvalues are
negative and the result follows. 
2.5. Existence of the KS present equilibrium, ε∗1
Setting the system (1)–(5) to zero and solving the resulting system simultaneously yields:








− μx1 = 0,









− μx1 = 0, (10)
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Using (5) to solve for X5 and replacing in (10) yields
A2X21 + A1X1 + A0 = 0,
where A2 = K2θx5 , A1 = μx1x1max + K2θx1θx5 + μx1θx5x1max(1 − R0) and A0 = μx1θx1
θx5x1max(1 − R0). To establish the existence of a positive root for g(X1) = A2X21 + A1X1 +
A0, say X∗1 , we argue as follows:




This implies that there is a positive number, X∗1 ∈ (0,+∞) such that g(X∗1 ) = 0. In par-
ticular, we one can show that X∗1 = −A1+
√
A21−4A0A2
2A2 . Hence, we obtain the following
























































Theorem 2.2: The endemic equilibrium, ε∗1 , exists ifR0 > max{1,Rf }.
We define Rf as the infectivity resistance threshold which must be exceeded for the
infection of progenitor cells to occur. The concept of pathogen load in relationship to
infectivity is discussed in many studies (see , e.g. [21]).
Remark 2.1: From (11)–(15), we deduce the following scenarios:
(a) IfRf < 1 < R0, then the endemic steady state ε∗1 = (X∗1 ,X∗2 ,X∗3 ,X∗4 ,X∗5 ) exists since,
X∗i = 0, i = 1, 2, 3, 4, 5. For Rf < 1, the risk of developing KS exists for any R0 >
1. The review article by Jeffrey et al. [21] has summarized the circulating levels of
infectious agents and the likelihood of infectivity from these levels. We identify in this
study the state ε∗1 as one of the levels of infectivity of KS.
(b) Despite the inequality in Theorem 2.2, that is, R0 > max{1,Rf }, it is interesting to
note that forR0 = Rf the components X∗3 and X∗4 vanish but the components X∗1 and
X∗2 are nonzero giving rise to the KS free equilibrium, ε
∗
2 = (X∗1 ,X∗2 , 0, 0,X∗5 ). We can
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Figure 2. PRCCs for parameters of the MIM and log(R0) as a function of the most sensitive parameter,
K2: (a) scatter plot forR0 and (b) PRCCs for the model.
calculate the critical value X∗2f for specified parameter values in (11) below which the
HHV-8 viral load is sufficient to maintain the replication of HHV-8 virions only but
is not high enough to support the secondary infection of progenitor cells which can
lead to the development of KS. The endemic point ε∗2 is, however, the starting point
for the next KS state , ε∗3 , discussed below.
(c) For R0 ∈ [1,∞) \ [1,Rf ], X2(t) > X∗2f , X∗i = 0, 1, 2, 3, 4, 5, giving rise to the KS
present equilibrium, ε∗3 . In this case like, in (a), the HHV-8 viral load is sufficient to
support both the primary infection of B cells and the secondary infection of progenitor
cells making the development of KS real.
(d) Note that for 1 < R0 < Rf , the endemic equilibrium point does not exist by virtue
of Theorem 2.1.
(e) We conclude that KS does not necessarily develop becauseR0 > 1, but it is sufficient
thatR0 > Rf . (see (b) and (d)).
We can summarize the results for the innate model as follows:
Lemma 2.2: Consider the system (1)–(5). The following statements hold:
(i) IfR0 < 1, then the virus free equilibrium, ε0, is the only equilibrium point.
(ii) If R0 > Rf , then there exist three possible equilibria: the KS-present equilibrium,
ε∗1 , for Rf < 1 < R0, the KS-free equilibrium, ε∗2 , for R0 = Rf and the KS-present
equilibrium, ε∗3 , forR0 ∈ [1,∞) \ [1,Rf ].
(iii) For 1 < R0 < Rf , no equilibrium point exists by virtue of Theorem 2.1.
3. Numerical simulations of theMIM
The parameter values used in Figure 2 are given in Table A1. Figure 2 shows the sensitiv-
ity analysis demonstrating how the model parameters are correlated to the reproduction
number, R0. We have found that the rate of infected B-cell proliferation, K2, is posi-
tively and significantly correlated with the reproduction number, a conclusion supported
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Table 1. Parameters of the MIM and their definitions.
Variable Definition Initial Value Reference
X1 Infected B cells 0 cell mm−3 Estimated
X2 HHV-8 viral load 0 cell mm−3 Estimated
X3 Infected progenitor cells 0 cell mm−3 [25]
X4 KS cells 0 cell mm−3 Estimated
X5 Innate immune response 10−2 Estimated
Parameter Definition Value Reference
K1 Infected progenitor cell proliferation rate 0.2 day−1 Estimated
K2 Infected B-cell proliferation rate 0.36 day−1 [31]
K3 Innate immune response activation rate 0.01 day−1 [31]
θx1 Innate immune response activation threshold 200 cell mm
−3 Estimated
θx5 Efficacy threshold for innate immune response 0.08 Estimated
x1max Infected B-cell carrying capacity 400 cell mm
−3 [31]
x2max HHV-8 carrying capacity 5 × 105 virions mm−3 [31]
μx1 Death rate of infected B cells 0.33 day
−1 [31]
μx2 Clearance rate of HHV-8 0.57 day
−1 [31]
μx3 Blanket death rate of infected progenitor cells 0.1 day
−1 [31]
μx4 Death rate of KS cells 0.03 day
−1 [31]
μ̂x3 Progression rate of KS 0.09 day
−1 [31]
Nx2 Maximum carrying capacity of infected B cells 700 [31]
by experimental observations by [13]. The other model parameters are not significantly
correlated toR0, and their effect on disease progression is peripheral.
The parameter values used in Figure 3 are given in Table 1. Figure 3 demonstrates the
effect of the parameter θx5 on disease progression. In particular, we have found a threshold
value for θx5 given by θ∗x5 ≈ 0.0205, below which the HHV-8 infection clears even ifR0 >
1. This condition suggests that a potential anti-KS therapy can be found, probably involving
pro-inflammatory cytokines such as IL-2 that have already demonstrated the potential to
stimulate type I immunity [28,29]. We recommend that experimental and clinical studies
should be conducted to assess the therapeutic effects associatedwith the parameter, θx5 , and
quantify its effect in reducing the KS load. We believe that clinical studies are necessary to
establish the severity of the infections in (a) and (c) and the possible location of the cancer
[19].
TheMIMgave a very important result regarding the development of KS. First, themodel
has identified three possible equilibria: ε∗1 , which exists forRf < 1 < R0, theKS-free equi-
librium, ε∗2 , which exists forR0 = Rf and ε∗3 which exists forR0 ∈ [1,∞) \ [1,Rf ]. We
recommend clinical studies to establish the severity and location of KS for the two equilib-
ria, ε∗1 and ε
∗
3 . The equilibrium state, ε
∗
3 , is possibly the most common in HHV-8 infected
individuals as most of them never develop KS as a result of a high infectivity resistance
threshold.
ForR0 = Rf , the populations of infected progenitor cells and KS cells vanish. For this
value of R0, only the primary infection of B cells and replication of HHV-8 take place.
Specifically, KS cannot develop, while forRf < R0 both the production of HHV-8 and KS
cells take place.
The MIM will be used to extract the initial conditions for the MAM in the next section
for the state variables, Xi(t), i = 1, 2, . . . , 5 and the parameters θx5 and Rf for which KS
can occur. We want to study the efficacy of the externally administered drugs that can
clear/reduce the KS load.
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Figure 3. Dynamics of the individual components of the MIM for different values of the efficacy thresh-
old θx5 . The HHV-8 infection clears for θx5 < θ
∗
x5 even ifR0 > 1: (a) infected progenitor cells, (b) KS cell
dynamics, (c) infected B-cell dynamics, (d) HHV-8 dynamics, (e) Innate immune response.
4. MODELWITH ADAPTIVEMECHANISM (MAM)
4.1. Model formulation and description
In case of HIV-1 and HHV-8 co-infection, a more robust adaptive immune response is
developed which includes virus-specific effector cells. Their interaction with the infected
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and uninfected cell and virus populations is modelled below and depicted in Figure 4. For
simplicity of notation, we denote
xi := xi(t), and x0i := xi(0), i = 1, 2, . . . , 10, (16)
where x1, x2, x3, x4 in that order denote the uninfected CD4 T, B-cell populations, HHV-
8 and HIV-1-specific effector cells, x5, x6, x7, x8 denote the infected CD4 T cells, B-cell,
progenitor cell populations and KS cells, respectively and finally, x9, x10 are the HIV-1 and
HHV-8 virions.
We have formulated the adaptive immune response described by the following system
of equations:
ẋ1 = 1 + 1α5x9x9 + S9 +
1α6x10
x10 + S10 − μ1x1 − β1x1x9. (17)
Equation (17) describes the dynamics of the susceptible CD4 T cells, x1. The first term
in (17) represents the constant natural replacement, 1, of the CD4 T cells, x1, the second
term represents proliferation of a proportion of circulating x1 cells due to the presence
of HIV-1 virions, at the constant rate, α5, and the third term represents proliferation of a
proportion of circulating x1 cells due to the presence ofHHV-8 virions, at the constant rate,
α6. There are two proliferation terms because proliferation is pathogen dependent [16,18].
The fourth term is the natural death of these cells at a constant rate, μ1, and the fifth term
represents infection of x1 cells by HIV-1 at a constant infection rate β1, and S9 and S10 are
half saturation constants of proliferation for HIV-1 and HHV-8, respectively.
ẋ2 = 2 + 2α5x9x9 + S9 +
2α6x10
x10 + S10 − μ2x2 − β2x2x10. (18)
Equation (18) describes the dynamics of the susceptible B cells, x2. The first term repre-
sents the constant natural replacement, 2, of the B cells, x2, the second term represents
the proliferation of a proportion of circulating x2 cells due to the presence of HIV-1 viri-
ons, at the constant rate, α5, and the third term represents proliferation of a proportion
of circulating x2 cells due to the presence of HHV-8 virions, at the constant rate, α6. As
in (17), there are two pathogen-dependent proliferation terms [16,18]. The fourth term is
the natural death of these cells at a constant rate,μ2, and the fifth term represents infection
of x2 cells by HHV-8 at a constant infection rate, β2.
ẋ3 = 3 + 3c10x10x10 + f10 − μ3x3. (19)
Equation (19) describes the dynamics of HHV-8 specific effector cells, x3. The first term
represents constant replenishment, 3, of these cells from precursors. The second term
represents the proliferation of a proportion of circulating x3 cells due to the presence of
the HHV-8 virions, at a constant rate, c10 with the half saturation constant, f10. The last
term represents natural death of HHV-8 specific effector cells at the constant death rate,
μ3.
ẋ4 = 4 + 4c9x9x9 + f9 − μ4x4. (20)
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Similar to above, Equation (20) describes the dynamics of HIV-1 specific effector cells, x4.
ẋ5 = 1α5x9x9 + S9 +
1α6x10
x10 + S10 + β1x1x9 − m4x4x5 − μ5x5. (21)
Equation (21) represents a class of infected CD4 T cells, x5. The first term represents the
proliferation of a proportion of circulating,x5, cells due to the presence of HIV-1 virions
and the second term represents the proliferation of a proportion of circulating,x5, cells due
to the presence of HHV-8 virions. The third term is the gain from infection of T cells by
HIV-1. The fourth term is the lysing of infected CD4T cells byHIV-1 specific effector cells,
at a constant term,m4, and the last term represents natural death of these cells at a constant
rate, μ5.
ẋ6 = 2α5x9x9 + S9 +
2α6x10
x10 + S10 + β2x2x10 − m3x3x6 − μ6x6. (22)
Similar to above, Equation (22) represents a class of infected B cells, x6. The first two terms
represent proliferation terms, the third is a gain from the infection of B cells and the fourth






− μ7x7 − d3x3x7. (23)
Equation (23) represents the dynamics of infected progenitor cells. The first term accounts
for the logistic growth rate of these cells that is assumed to depend on HHV-8. The sec-
ond term is the progression of these cells to KS at a constant rate μ7 [13]. The third term
represents the killing of these cells by HHV-8 specific effector cells at a constant rate d3.
ẋ8 = μ7x7 − μ8x8. (24)
Equation (24) represents the dynamics of KS. The first term represents the source from
infection of progenitor cells. The second term represents natural loss of KS cells.
ẋ9 = N9μ5x5 − μ9x9. (25)
Equation (25) represents the dynamics of HIV-1. The first term represents the production
of virions from the bursting of the infected CD4 T cells. The parameter N9 represents the
maximum carrying capacity of infected CD4 T cells. The second term is the clearance rate
of HIV-1.
ẋ10 = N10μ6x6 − μ10x10. (26)
Equation (26) represents the rate of change of HHV-8. The first term represents the rate
at which HHV-8 is produced from bursting of the infected B cells. The parameter N10
represents the maximum carrying capacity of infected B cells. The last term accounts for
the clearance rate of HHV-8.
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4.2. Analysis of themodel
4.2.1. Positivity and boundedness of solutions
From Equations (25)–(26), we have xi(t) ≥ xi(0)exp(−μit) ≥ 0, for all t ≥ 0 and i = 9,
10. To prove the positivity and ensure that the model (17)–(26) is well-posed, we use the
following two conditions, (C1) and (C2):
(C1) : f (x9, x10) = x9x9 + S9 +
x10
x10 + S10 ≥ 0, for all (x9, x10) ∈ R
2
+.





≥ 0, for 0 ≤ x ≤ xmax
2
.
Lemma 4.1: Consider the system (17)–(26) and assume that (C1) and (C2) hold.
(a) If xi(0) ≥ 0, i = 1, 2, 3, . . . , 10, then the solution xi(t) ≥ 0, for all t > 0.
(b) Moreover, xi(t) < ∞, i = 1, 2, . . . , 10, for all t ≥ 0.
First we will rearrange the system (17)–(26) into a subsystem of uninfected (S1) states
(Equations 17–20) and infected (S2) states (Equations 21–26). It will be shown that if the
noninfected states in (S1) are non-negative for all t ≥ 0, then the infected states in (S2) are
non-negative for all t ≥ 0.










⎠ xi + ̂i (27)
where Bij ≥ 0, ̂i = Li(x9, x10), for i = 1, 2, 3, 4. The last component is defined as


























Clearly, ̂(0, 0) > (0, 0, 0, 0)T by virtue of (A1). Suppose the assertion xi(t) ≥ 0 for i =
1, 2, 3, 4 is not true. Then there exists a smallest number t0, such that
xi(t) < 0 for 1 ≤ i ≤ 4, 0 ≤ t ≤ t0
xi(t0) = 0 for at least one i, say i0.
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However, from the differential inequality (27) for xi0(t) we get
dxi0(t0)
dt
≥ π̂i > 0
which is a contradiction. Hence, if xi(0) ≥ 0, i = 1, 2, 3, 4, then xi(t) ≥ 0 for all t > 0, i =
1, 2, 3, 4.
The subsystem of infected states (S2) can be written in the matrix form Ẏ(t) = MY ,




−M11 0 0 0 M15 M16
0 −M22 0 0 M25 M26
0 0 −M33 0 0 M36
0 0 μ7 −μ8 0 0
N9μ5 0 0 0 −μ9 0




M11 = μ5 + m4x4, M22 = μ6 + m3x3,
M33 = μ7 + d3x3, M15 = α51S9
(x9 + S9)2 + β1x1,
M16 = α61S10
(x10 + S10)2 , M25 =
α52S9
(x9 + S9)2 ,
M26 = α62S10






By virtue of (A1) and (A2),M is a Metzler matrix. Hence, the infected states xi(t) ≥ 0 for
all t>0, i = 5, 6, 7, 8, 9, 10. 
The proof of Lemma 4.1(b) is given in the Appendix.
4.3. Virus free equilibrium and the basic reproduction number














, 0, 0, 0, 0, 0, 0
)
. (28)
Applying the next-generation matrix approach [32], the basic reproduction number for
model (17)–(26) reads as follows:
R0 = 12
[
RV1 + RV8 +





























are the reproduction numbers attributed to HIV-1 and HHV-8 infections, respectively.
Note that the effect of virus-specific effector cells in (30) varies from weak to perfect as














where R1, R8 are the reproduction numbers when the virus-specific effector cells are
dysfunctional.
Given (29)–(30) we make the following observations:
Observation 4.1: If α5 = 0 or α6 = 0, then 
 = 0 and the model reproduction number
is given byR0 = max{RV1 ,RV8}.
Observation 4.2: Decreasing/increasing α5 or α6 decreases/increases the reproduction
number. Since α5 and α6 are the proliferation terms of the uninfected/infected B- and T-
cell populations, an optimal control approach will be necessary that will balance the level
of proliferation during a potential chemo- or immunotherapy.
Observation 4.3: When 
 = 1, the reproduction number reduces to
R0 = 12
[




= RV1 + RV8 . (32)
It is possible in this case for the infection to persist ifRV1 + RV8 > 1, even if bothRV1 < 1
andRV8 < 1·
Details on the computation of the reproduction number,R0, and the interpretation of
Ri andRVi for i = 1, 8, the reader is directed to the appendix.
4.3.1. Global stability for the virus free equilibrium, ε0
Theorem 4.1: Decompose the system (17)–(26) as in Lemma A.1 in the Appendix. Then
the steady state U0 = (X∗, 0) of the system (17)–(26) is globally asymptotically stable for
α5 = α6 = 0 andR0 < 1.











. Then following [9], we set X = (x1, x2, x3, x4),




























































, j = 5, 6.
The global stability of the system (17)–(26) at ε0 requires that Ĝ(X,Y) ≥ 0 [13]. Moreover,
x∗i > x
0
i , for i = 3, 4 and x0j > x∗j , for j = 1, 2. Then X∗ is a globally asymptotically sta-
ble solution of the system dXdt = F(X, 0) since F(X, 0) is the limiting function of dXdt =
F(X(t),Y(t)), that is, limt→∞ X(t) = X∗. It follows that Ĝ(X,Y) ≥ 0 and so ε0 is globally
asymptotically stable. 
4.4. AIDS-KS-present equilibrium, E∗
Theorem 4.2: Consider the system (17)–(26). The KS present equilibrium, E∗, exists if 0 <




































































































) = α5x∗9x∗9+S9 + α6x∗10x∗10 , ζ2(x∗10) = c10x∗10x∗10+f10 .
(33)
where x∗9 and x
∗
10 are proved to be positive solutions of the fourth degree polynomials
Qi, i = 1, 2. The reader is directed to the appendix for details.
230 O. MULENGA CHIMBOLA ET AL.
Remark 4.1: Observe that when x∗9 = 0 and x∗10 = 0, we obtain the virus free equilibrium,
ε0 in Equation (28).
4.5. Non-AIDS-KS-present equilibrium, E∗∗
Theorem 4.3: Consider the system (17)–(26). The non-AIDS-KS-present equilibrium, E∗∗,

































, x∗∗9 = 0.
(34)














D2 = N102β2μ3μ6 − 3m3μ2μ10 − μ2μ3μ6μ10 − 3S10β2m3μ10
−3β2f10m3μ10 − 3c10m3μ2μ10 − S10β2μ3μ6μ10
−β2f10μ3μ6μ10 + 2N102α6β2μ3μ6 − 3S10β2c10m3μ10,
D1 = N102S10β2μ3μ6 − 3f10m3μ2μ10 − S10μ2μ3μ6μ10
−f10μ2μ3μ6μ10 − 3S10m3μ2μ10





)(RV8 − 1) > 0, if and only if RV8 > 1.
(36)
Note that G(0) = D0 > 0 if and only if RV8 > 1. Using the continuity property of cubic
polynomials, we have limx10→∞ G(x10) = −∞. Hence, there must be a positive value of
x10, namely, x∗∗10 ∈ (0,∞) such that G(x∗∗10 ) = 0.
5. Numerical simulations of theMAM
Figure 5 shows the sensitivity analysis of parameters from Table A2 onR0. The maximum
carrying capacity of infected B cells is strongly positively correlated withR0, whereas the
HHV-8 clearance rate has the opposite effect. The logarithm of the reproduction number
as a function of these two parameters is also shown. For small values ofN10, the increase is
fast, implying that one can overestimate the severity of the infection. For large values ofN10,
the increase is slow, implying that disease progression is stable and the conclusions are not
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Figure 4. Schematic diagram for the MAM.
adversely affected. The relationship between the log(R0) and the clearance rate of HHV-8
virions is almost linear, suggesting a moderate negative correlation with the progression of
AIDS-KS.
The parameter values used in Figures 6–8 are given in Table 2. Assuming an advanced
HIV-1 and HHV-8 co-infection stage, the initial condition of the system (17)–(26) was
chosen to be the equilibrium point of the system (1)–(5). Figure 6 shows the dynamics
of the uninfected/infected B cells and CD4 T cells, infected progenitor cells, KS cells and
virions for a period of 300 days. The population of infected CD4 T cells reaches a peak
at 100 days by then the population of infected B cells have already reached a steady state.
These results, in line with experimental evidence, support the fact that KS may accelerate
the clinical course of HIV-1 infection.
Figure 7 compares the long-term dynamics of HIV-1 and HHV-8 populations with
uninfected CD4 T and B cells. The uninfected CD4 T-cell population starts declining
rapidly after about 300 days and the HIV-1 population switches from a stable to an expo-
nential growth after about 6 years. For the infected B-cell population, this switch occurs
after about 8 years. The delay in the switching time from a stable to exponential growth
between theHIV-1 andHHV-8 viral load indicates thatHHV-1 supports the clinical course
of KS. Figure 8 shows that the uninfected CD4 T-cell population peaks at about 60 days, 40
days before the HIV-1 peak and that the KS cell population will have a steeper rise than the
relatively stable infected B-cell population. This suggests that at later stages of AIDS-KS,
the reservoirs of HHV-8 will be predominantly the infected progenitor cells.
6. Optimal control applied to theMAM
We now apply an optimal control approach to the system (17)–(26). In order to deter-
mine the optimal strategy for controlling AIDS-KS with cART, we introduce three time-
dependent controls: u1(t), u2(t) and u3(t). The control u1(t) is the efficacy of HAART for
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Figure 5. PRCCs for parameters of the MAM and log(R0) as a function of the two most sensitive
parameters, N10 and β2: (a) scatter plot forR0, (b) scatter plot forR0 and (c) PRCCs for the model.
preventing the infection of CD4T cells byHIV-1 and u2(t) is the efficacy ofHAART in pre-
venting the infection of B cells by HHV-8. The third control u3(t) represents the efficacy
of an anti-KS therapy by enhancing the proliferation of CD4 T and B cells.
ẋ1 = 1 + (α5(1 − u3(t))) x9x9 + S9 1 +
(εα5(1 − u3(t))) x10
x 10
+ S101 − μ1x1 − (1 − u1(t)) β1x1x9. (37)
Equation (37) describes the dynamics of the uninfected CD4 T cells. The meanings of the
various terms are given in Equation (17). However, the proliferation constants, αi, i =
5, 6 in (17) are now replaced by (α5(1 − u3)) and (εα5(1 − u3)), respectively. Note that
α6 is here assumed to be a multiple of α5, with ε being the constant of proportionality,
which is purely done for technical reasons. The infection coefficient, β1, is replaced by
(1 − u1(t))β1, where u1(t) is the efficacy of HAART in preventing the infection of healthy
CD4 T cells and hence, u1(t) could represent treatment with either the fusion inhibitor or
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Figure 6. Dynamics of the individual components of the MAM forR0 = 1.7902: (a) uninfected CD4 T
cells and infected CD4 T-cells; (b) uninfected B cells and infected B cells; (c) infected progenitor cells and
KS cells, and (d) HIV-1 and HHV-8.
Figure 7. Comparison of the long-term dynamics of the uninfected CD4 T cells and B cells with regard
to HIV-1 and HHV-8 load: (a) HIV-1 and uninfected CD4 T cells and (b) HHV-8 and uninfected B cells.
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Figure 8. (a) Same as Figure 7(a) but for the first 300 days. (b) The long-termdynamics of infected B cells
and KS cells with regards to HHV-8 load: (a) HIV-1 and uninfected CD4 T cells and (b) KS cells, HHV-8 and
infected B-cell dynamics.
the reverse transcriptase inhibitor.
ẋ2 = 2 + (α5(1 − u3(t))) 5x9x9 + S9 2
+ (εα5(1 − u3(t))) x10
x10 + S10 2 − μ2x2 − (1 − u1(t)) β2x2x10. (38)
Equation (38) describes the dynamics of the susceptible B cells. The meanings of the vari-
ous terms are given in Equation (18). The second and third terms are explained in E (37).
The first and fourth terms are explained in Equation (18). The infection coefficient, β2, is
replaced by (1 − u1(t))β2, where u1(t) is the efficacy of HAART in preventing the infec-
tion of healthy B cells. It is well documented that AIDS-KS patients undergoing HAART
treatment undergo remission and hence, we assume that HAART treatment reduces the
infection rate of B cells by HHV-8.
ẋ3 = 3 + c103x10x10 + f10 − μ3x3. (39)
Equation (39) describes the dynamics of HHV-8 specific effector cells, x3. The terms are as
explained in Equation (19).
ẋ4 = 4 + c94x9x9 + f9 − μ4x4. (40)
Equation (40) describes the dynamics of HIV-1 specific effector cells, x4.The terms are as
explained in Equation (20).
ẋ5 = (α5(1 − u3(t))) x9x9 + S9 1 +
(εα5(1 − u3(t))) x10
x10 + S10 1
+ (1 − u1(t)) β1x1x9 − m4x4x5 − μ5x5. (41)
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Table 2. Parameters of the MAM and their definitions.
Variable Definitions Initial value Reference
x1 Uninfected CD4 T cells 105 cell ml−1 [25]
x2 Uninfected B cells 104 cell ml−1 Estimated
x3 HHV-8 effector cells cell ml−1 MIM
x4 HIV-1 effector cells 104 cell ml−1 Estimated
x5 Infected CD4 T cells 300 cell ml−1 Estimated
x6 Infected B cells 32.4 cell ml−1 MIM
x7 Infected progenitor cells 61.3 cell ml−1 MIM
x8 KS cells 30.1 cell ml−1 MIM
x9 HHV-1 virions 100 virions ml−1 Estimated
x10 HHV-8 virions 83.6 cell ml−1 MIM
Parameter Definitions Value Reference
α5 HIV-1-dependent enhancement of CD4 T-cell proliferation 0.013 Estimated
α6 HHV-8-dependent enhancement of CD4 T-cell proliferation 0.045 Estimated
β1 Infection rate of CD4 T cells by HIV-1 2.4 × 10−8 ml virion−1 day−1 [31]
β2 Infection rate of B cells by HHV-8 1.5 × 10−7 ml virion−1 day−1 [31]
1 Source of new CD4 T cells from the thymus 104 cell ml−1 day−1 [31]
2 Source of new B cells from the bone marrow 48000 cell ml−1 day−1 [31]
3 Constant source of HHV-8 specific effector cells 5 × 103 cell ml−1 day−1 Estimated
4 Constant source of HIV-1 specific effector cells 2 × 104 cell ml−1 day−1 [31]
S9 Half saturation for HIV-1-stimulated CD4 T-cell proliferation 3 × 105 virions ml−1 Estimated
S10 Half saturation for HHV-8-stimulated CD4-T cell proliferation 2 × 105 virions ml−1 Estimated
μ1 Death rate of CD4 T cells 0.01 day−1 [31]
μ2 Death rate of B cells 0.24 day−1 [31]
μ3 HHV-8 specific effector cell death rate 0.1 day−1 [31]
μ4 HIV-1 specific effector cell death rate 0.1 day−1 [31]
μ5 Lytic death rate of infected CD4 T cells 0.24 day−1 [31]
μ6 Death rate of free HHV-8 virus 0.33 day−1 [31]
μ7 KS progression rate 0.1 day−1 [31]
μ8 Natural death rate of KS cells 0.21 day−1 [31]
μ9 Clearance rate of HIV-1 virions 3 day−1 [31]
μ10 clearance rate of HHV-8 virions 0.57 day−1 [31]
N9 Maximum carrying capacity of infected CD4 T cells 1000 virions cell−1 [31]
N10 Maximum carrying capacity of infected B cells 700 virions cell−1 [31]
m3 Killing rate of HHV-8 infected B cells 1.08 × 10−4 ml cell−1 day−1 Estimated
m4 Killing rate of HIV-1 infected CD4 T cells 2 × 10−7 ml cell−1 day−1 Estimated
c9 Proliferation rate of HIV-1 specific CTLs due 0.03 [31]
c10 Proliferation rate of HHV-8 specific CTLs 0.047 [31]
d3 Killing rate of infected progenitor cells 5 × 10−4 ml cell−1 day−1 Estimated
r7 Maximum proliferation rate of infected progenitor cells 0.33 cells virion−1 day−1 [31]
f9 Half saturation for proliferation of HIV-1 specific CTLs 3 × 105 virions ml−1 Estimated
f10 Half saturation for proliferation of HHV-8 specific CTLs 2 × 105 virions ml−1 Estimated
x10max Maximum HHV-8 load 8 × 109 virions ml−1 Estimated
Equation (41) represents a class of infected CD4 T cells, x5. The first two terms are as
explained in (37) and (38) above. The third term is the gain from Equation (37) and the
other terms are as explained in Equation (21).
ẋ6 = (α5(1 − u3(t))) x9x9 + S9 2 +
(εα5(1 − u3(t))) x10
x10 + S10 2
+ (1 − u1(t)) β2x2x10 − m3x3x6 − μ6x6. (42)
Equation (42) represents a class of infected B cells, x6. The first two terms are as explained
in (41) above. The third term is the gain from Equation (38) and the other terms are as
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explained in Equation (22).





− μ7x7 − d3x3x7. (43)
Equation (43) represents the dynamics of infected progenitor cells. In the first term, the
logistic growth rate r7 is reduced by a factor (1 − u1(t)) due to the action of HAART in
blocking the infection of progenitor cells by HHV-8. The other terms are as explained
before in Equation (23).
ẋ8 = μ7x7 − μ8x8. (44)
Equation (44) represents the dynamics of KS. The terms are already explained in
Equation (24).
ẋ9 = N9μ5 (1 − u2(t)) x5 − μ9x9. (45)
Equation (45) represents the HIV-1 dynamics. The first term is decreased by a factor 1 −
u2(t) to reflect the action of HAART in blocking the production of infectious and mature
HIV-1 virions. The other term is explained in Equation (25).
ẋ10 = N10μ6 (1 − u2(t)) x6 − μ10x10. (46)
Similar to Equation (45), Equation (46) represents the HHV-8 dynamics.
To this end, we consider the objective (or cost) functional















where the control functions u1(t), u2(t) and u3(t) are bounded, Lebesgue integrable
functions on [0,Tf ] and Ai,Bi, i = 1, 2, 3 are positive constants.
6.1. Existence of optimal control
Our control problem is formulated by minimizing the functional J subject to the sys-












) = min {J (u1, u2, u3) |u1, u2, u3 ∈ U} (48)
where
U = {(u1, u2, u3) suchthat u1, u2, u3 are measurable with 0 ≤ ui ≤ 1, for t ∈ [0,Tf ]}
(49)
is the control set.
The necessary conditions that an optimal solution must satisfy come from the Pon-
tryagin et al. [26] maximum principle. This principle converts the system (37)–(46) with
Equation (47) into a problem of minimizing pointwise a Hamiltonian H, with respect to
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− μ7x7 − d3x3x7
)








)+ λx10 (N10μ6(1 − u2)x6 − μ10x10) (50)
where x = (x1, x2, . . . , x10), u = (u1, u2, u3), λx = (λx1 , λx2 , . . . , λx10) and λxi , i =
1, 2, . . . , 10 are the adjoint or co-state variable corresponding to the state variable xi. The
system of equations is found by taking appropriate partial derivatives of the Hamiltonian
with respect to the associated state variable, xi.




3 that minimize J(u1, u2, u3) over U, and the
solutions x1, x2, . . . x10 of the corresponding state system (37)–(46) with Equation (47), then








































x9 + S9 +
εα5x10
x10 + S10
) (1(λx1 + λx5)+ 2(λx2 + λx6))
B3
.
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Proof: Corollary 4.1 of Fleming and Rishel [12] gives the existence of an optimal con-
trol due to the convexity of the integrand of J with respect to u1, u2 and u3. In addition,
it also guarantees a-priori boundedness of the state solutions and the Lipschitz prop-
erty of the state system with respect to the state variables. The differential equations
governing the adjoint variables are obtained by differentiation of the Hamiltonian func-


























= μ3λx3 + m3x6λx6 + d3x7λx7 ,
dλx4
dt

































)2 (1(λx1 + λx5)+ 2(λx2 + λx6))
+ (1 − u1)β1x1(λx1 − λx5)− c94f9(
x9 + f9









)2 (1(λx1 + λx5)+ 2(λx2 + λx6))
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ûi, if 0 < ûi < 1;
0, if ûi ≤ 0;
1, if ûi ≥ 1.







, i = 1, 2 and u∗3 =
⎧⎨
⎩
û3, if 0 < û3 < 0.5;
0, if û3 ≤ 0;
1, if û3 ≥ 0.5.








7. Numerical simulations of optimal treatment regiments




3 in the first 20 days. The
initial values u∗i (20), i = 1, 2, 3 are used in an iterative procedure for periods much longer
than 20 days. Figure 10 depicts the dynamics of the infected cell populations and viral
loads for fixed values of u2 and u3 during 300 days for different values of the HAART
efficacy parameter u1. For optimal efficacy u∗1 ≈ 0.79, the HIV-1 and HHV-8 populations
drop below the level of detection. This parameter combination, however, is not unique as
illustrated in Figure 11, which shows that reduced infected CD4 T-cell-specific HAART
efficacy (from u∗1 ≈ 0.79 to u∗1 ≈ 0.67) and increased infected B-cell-specific HAART effi-
cacy (from u∗2 ≈ 0.48 to u∗2 ≈ 0.68) in combination with reduced KS therapy-specific
efficacy (from u∗3 ≈ 0.25 to u∗3 ≈ 0.15) is also able to control HIV-1 and HHV-8 co-




3) but this is not unique. This conclusion
makes it easier to develop cheaper combinations that would suit the budgets of developing
countries.
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Figure 10. Population dynamics of infected cells and viruses during 300 days for varying values of the
infected CD4 T-cell-specific HAART efficacy u1: (a) infected T cells with u2 = 0.48, u3 = 0.25; (b) infected
B cellswithu2 = 0.48, u3 = 0.25; (c) infectedprogenitor cellswithu2 = 0.48, u3 = 0.25; (d) KS cellswith
u2 = 0.48, u3 = 0.25; (e) HIV-1 with u2 = 0.48, u3 = 0.25; (f ) HHV-8 with u2 = 0.48, u3 = 0.25.
8. Discussion
Currently there is no treatment available to eradicate HHV-8 infection and the purpose
of anti-KS therapies is directed at slowing disease progression. KS is the most common
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Figure 11. Population dynamics of infected cells and viruses during 300 days for a new combination of
optimal controls: (a) Infected T cells with u2 = 0.68, u3 = 0.15; (b) infected B cells with u2 = 0.68, u3 =
0.15; (c) infected progenitor cells with u2 = 0.68, u3 = 0.15; (d) KS cells with u2 = 0.68, u3 = 0.15; (e)
HIV-1 with u2 = 0.68, u3 = 0.15; (f ) HHV-8 with u2 = 0.68, u3 = 0.15.
neoplasm associatedwithAIDS and hence, therapies centre on the use ofHAART inAIDS-
KS patients. In this work, we formulate two models with innate and adaptive mechanism,
in order to study the dynamics of non-AIDS KS and AIDS-KS and to make predictions
about the efficacy of anti-KS therapies.
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Some evidence suggests that immune activation is a requisite for the development of
Classic KS [11,22]. Hence, we included the effect of the immune response in the MIM and
showed that in silico treatment of NAKS can significantly reduce HHV-8 infection. We
determined a critical value of the efficacy threshold for the innate immune response below
which KS burden is diminished even ifR0 > 1. This is completely novel to the best of our
knowledge and has important implications, since therapies involving cytokines such as IL-
2 [28] may have adverse side effects. Because it is not known how long the innate response
forHIV-1 andHHV-8 co-infection lasts, this study is not able to suggest the dosage and fre-
quency of treatment regimen. It is hoped a clinical study can explore the potential revealed
by this study.
About 30% of Classic KS patients develop a second malignancy like non-Hodgkin
lymphoma [10], hence, an early diagnosis that may prevent second malignancies is essen-
tial. The MIM demonstrated the potential for controlling HHV-8 infection and con-
sequently, also HIV-1 and HHV-8 co-infection. Currently, there are early HIV-1 tests
capable of revealing that an individual has been in contact with someone infected with
HIV-1 (http://hivinsite.ucsf.edu/insite?page=basics-01-01). The strategy described in this
study can be used to prevent HIV-1 infections before they develop for example in rape
victims who are treated with antiretroviral drugs for 28 days immediately after the
crime.
In the absence of any treatment the long-term prognosis of AIDS-KS is poor. This is
shown by Figures 7 and 8 of the MAM. However, if cART (e.g. HAART plus KS ther-
apy) is administered at optimal levels, both HIV-1 and HHV-8 infection can decline to
undetectable levels (Figures 10 and 11). The simulations indicate that HAART at subop-
timal levels cannot eradicate the viral load, which can possibly lead to the emergence of
drug-resistance mutations [2]. For cART, when the efficacy of a potential fusion inhibitor
or reverse transcriptase inhibitor is kept at optimal level, a very low level efficacy for KS
therapy is sufficient to control the HHV-8 infection.
The implications of our study are three-fold. First, early intervention in the form of KS-
therapy can control HHV-8 infection from developing into KS and possibly also slowHIV-
1 infection to develop intoAIDS. Second, optimal control ofHIV-1 infection usingHAART
is an integral part of a successful AIDS-KS therapy and should be used in combinationwith
low-level KS therapy. These recommendations have the potential to impact the therapeutic
goal in KS, by focusing on short term control and thus, aiding long-term remission. Third,
it is hoped that the existence of an infectivity threshold, which is critical for the progression
of KS from asymptomatic to symptomatic stage, can help to study for example, the HHV-8
infectivity of transfusions [1].
The MIM revealed that externally administered cytokine drugs can reduce the chances
of KS developing. This is supported in part by a study by [29,33] involving IL-2
and IL-12 which showed that administration of cytokines can prevent or delay the
development of infection. However, to the best of our knowledge there are no clin-
ical studies that have determined the safe levels of these cytokine drugs that can be
taken. Because it is not known how long the innate response for HIV-1/HHV-8 co-
infection lasts, this study is not able to suggest the dosage and frequency of treat-
ment regimen. We believe a clinical study can explore the potential revealed by our
study.
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Appendix
(i) Positivity and boundedness of solution
Lemma4.1 (b): Let y1(t) = x1(t) + x5(t) and y2(t) = x2(t) + x6(t) denote the total sub-populations
of the CD4+ T cells and B cells at time t, respectively, where xi(t) ≥ 0 by Lemma 1(a).









− μjxj − μj+4xj+4, j = 1, 2.
≤ j
(




−μ̂jyj(t), where μ̂j = min{μj,μj+4}
It is easy to show that as t → ∞, yj(t) ≤ Mjμ̂j , j = 1, 2. Equations (25) and (26) can be represented by
dxj(t)
dt
= Njμj−4xj−4 − μjxj ≤ Njμj−4
Mj−8
μ̂j−8
− μjxj j = 9, 10.
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(ii) Virus Free Equilibrium and the Basic Reproduction Number
The following refers to the reproduction numbers given in Section 4.3
RV1 =




(μ4μ5 + m44) <















From (A2) we can deduce that
• RVi , i = 1, 8 are the reproduction numbers when virus i specific effector cells are active but their
effect varies from being weak to perfect asmj, j = 3, 4, increases ·
• Ri, i = 1, 8 are the reproduction numbers when virus i specific effector cells are dysfunctional.
1. Let x = (x5, x6, x7, x8, x9, x10)T , y = (x1, x2, x3, x4)T . The system (17)– 26) can be written as
dx
dt
= F(x, y) − V(x, y),
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0 0 μ7 0 0 0
0 0 0 0 0 0


















0 0 0 μ8 0 0
−N9μ5 0 0 0 μ9 0


































0 0 0 0 0 0
0 0 0 0 0 0
⎞
⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎠
K1 = α5μ1 + β1S9, K2 = α6μ2 + β2S10, a11 = μ4μ5 + m44,
a22 = μ3μ6 + m33, a33 = μ3μ7 + d33
(A3)
(iii) Global stability for the virus free equilibrium, ε0






= G((X, I)), G(X, 0) = 0, (A4)
where X ∈ Rm denotes the components of the uninfected states, I ∈ Rn denotes the components of the
infected states and U0 = (X∗, 0) denotes the disease-free equilibrium of (A4). Assume the conditions








) = AI − Ĝ(X, I), Ĝ(X, I) ≥ 0 for (X, I) ∈ ,
where A = DIG(X∗, 0) is an M-matrix (the off diagonal elements of A are nonnegative) and  is the
region where the model makes biological sense. Then U0 is globally asymptotically stable.
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(iv) AIDS-KS present equilibrium, E∗
The coordinates x∗9 and x
∗
10 in Theorem 4.2 are positive solutions to Qi, i = 1, 2 where















B3 = N102S9β2μ3μ6 − S9μ2μ3μ6μ10 − 3m3μ2μ10x9 − μ2μ3μ6μ10x9 − 3S9m3μ2μ10
−3S9S10β2m3μ10 − 3S9β2f10m3μ10 − 3S9c10m3μ2μ10
−S9S10β2μ3μ6μ10 + N102β2μ3μ6x9
−3S10β2m3μ10x9 − S9β2f10μ3μ6μ10
−3β2f10m3μ10x9 − 3c10m3μ2μ10x9 − S10β2μ3μ6μ10x9
−β2f10μ3μ6μ10x9 + N101α5β2μ3μ6x9 + N101α6β2μ3μ6x9+
N102α5β2μ3μ6x9 + N102α6β2μ3μ6x9
−3S10β2c10m3μ10x9 + N101S9α6β2μ3μ6 + N102S9α6β2μ3μ6 − 3S9S10β2c10m3μ10
B2 = N102S10β2μ3μ6x9 − 3S9f10m3μ2μ10 − S9S10μ2μ3μ6μ10
−3S10m3μ2μ10x9 − S9f10μ2μ3μ6μ10
−3f10m3μ2μ10x9 − S10μ2μ3μ6μ10x9 − f10μ2μ3μ6μ10x9
−3S9S10m3μ2μ10 − 3S9S10m3μ2μ10
−S9S10β2f10μ3μ6μ10 + N102β2f10μ3μ6x9 − 3S10β2f10m3μ10x9 + N101α5μ2μ3μ6x9
+N101α6μ2μ3μ6x9
−3S10c10m3μ2μ10x9 − S10β2f10μ3μ6μ10x9 + N102S9S10β2μ3μ6
+N102S9β2f10μ3μ6 − 3S9S10β2f10m3μ10
+N101S9α6μ2μ3μ6 + N101S9α6β2f10μ3μ6 + N102S9α6β2f10μ3μ6
+N101S10α5β2μ3μ6x9 + N102S10α5β2μ3μ6x9
+N101α5β2f10μ3μ6x9 + N101α6β2f10μ3μ6x9 + N102α5β2f10μ3μ6x9
+N102α6β2f10μ3μ6x9
B1 = N102S9S10β2f10μ3μ6 − S9S10f10μ2μ3μ6μ10 − 3S10f10m3μ2μ10x9
−S10f10μ2μ3μ6μ10x9 − 3S9S10f10m3μ2μ10
+N101S9α6f10μ2μ3μ6 + N102S10β2f10μ3μ6x9 + N101S10α5μ2μ3μ6x9
+N101α5f10μ2μ3μ6x9 + N101α6f10μ2μ3μ6x9
+N101S10α5β2f10μ3μ6x9 + N102S10α5β2f10μ3μ6x9
B0 = N101S10α5f10μ2μ3μ6x9 > 0, forall x9 > 0.
(A6)
The existence of a positive value, x∗10, for Q1(x10) can be justified as follows:
Note that Q1(0) = B0 > 0. Due to the continuity of Q1(x10), we have limx10→∞ Q1(x10) = −∞
since B4 < 0. Hence, there exists a positive value for x10, say, x∗10 such that Q1(x
∗
10) = 0.
Using Equation (25) along with x∗10 just obtained above, we get
Q2(x9) = E4x49 + E3x39 + E2x29 + E1x9 + E0 = 0, (A7)
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Table A1. Range of parameters for sensitivity analy-





θx1 100–500 cell mm
−3
θx5 0.002–0.069
x1max 200–650 cell mm
−3
x2max 10
4−5.1 × 105 virions mm−3
μx3 0.1–0.3 day
−1





















E3 = N91S10β1μ4μ5 − S10μ1μ4μ5μ9 − 4m4μ1μ9x∗10 − μ1μ4μ5μ9x∗10 − 4S10m4μ1μ9
−4S9S10β1m4μ9 − 4S10β1f9μ4μ9 − 4S10c9m4μ1μ9
−S9S10β1μ4μ5μ9 + N91β1μ4μ5x∗10
−4S9β1m4μ9x∗10 − S10β1f9μ4μ5μ9
−4β1f9m4μ9x∗10 − 4c9m4μ1μ9x∗10 − S9β1μ4μ5μ9x∗10
+2N91α5β1μ4μ5x∗10 + 2N91α6β1μ4μ5x∗10 − 4S9β1c9m4μ9x∗10
+2N91S10α5β1μ4μ5 − 4S9S10β1c9m4μ9
E2 = N91S9β1μ4μ5x∗10 − 4S10f9m4μ1μ9 − S9S10μ1μ4μ5μ9
−4S9m4μ1μ9x∗10 − S10f9μ1μ4μ5μ9
−4f9m4μ1μ9x∗10 − S9μ1μ4μ5μ9x∗10 − f9μ1μ4μ5μ9x∗10
−4S9S10c9m4μ1μ9 − 4S9S10m4μ1μ9
−S9S10β1f9μ4μ5μ9 + N91β1f9μ4μ5x∗10 − 4S9β1f9m4μ9x∗10
+N91α5μ1μ4μ5x∗10 + N91α6μ1μ4μ5x∗10
−4S9c9m4μ1μ9x∗10 − S9β1f9μ4μ5μ9x∗10 + N91S9S10β1μ4μ5
+N91S10β1f9μ4μ5 − 4S9S10β1f9m4μ9
+N91S10α5μ1μ4μ5 + 2N91S10α5β1f9μ4μ5 + 2N91S9α6β1μ4μ5x∗10
+2N91α5β1f9μ4μ5x∗10 + 2N91α6β1f9μ4μ5x∗10
E1 = N91S9S10β1f9μ4μ5 − S9S10f9μ1mu4μ5μ9 − 4S9f9m4μ1μ9x∗10
−S9f9μ1μ4μ5μ9x∗10 − 4S9S10f9m4μ1μ9
+N91S10α5f9μ1μ4μ5 + N91S9β1f9μ4μ5x∗10 + N91S9α6μ1μ4μ5x∗10
+N91α5f9μ1μ4μ5x∗10 + N91α6f9μ1μ4μ5x∗10 + 2N91S9α6β1f9μ4μ5x∗10
E0 = N91S9α6f9μ1μ4μ5x∗10 > 0.
(A8)
Analogously, arguing as before, we can establish the existence of a positive value of x9, say, x∗9
satisfying Q2(x∗9) = 0.
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Table A2. Range of parameters for sensitivity analysis for the MAM.
Parameter Range Units
N9 100–1000 virions cell−1
N10 100–1000 virions cell−1
1 103−104 cell ml−1 day−1
2 70 × 103−4.275 × 105 cell ml−1 day−1
3 102−103 cell ml−1 day−1
4 104−3 × 104 cell ml−1 day−1
r7 0.045−0.055 cells virion−1 day−1
d3 5.47 × 10−5−1.09 × 10−4 ml cell−1 day−1
m3 5.47 × 10−5−1.09 × 10−4 ml cell−1 day−1
m4 10−7−10−5 ml cell−1 day−1
α5 10−2−1.5 × 10−4
α6 1.4 × 10−2−5.5 × 10−2
S9 2 × 105−5 × 105 virions ml−1
S10 105−3 × 105 virions ml−1
β1 2.4 × 10−8−2.5 × 10−7 ml virion−1 day−1
β2 4.75 × 10−9−4.75 × 10−7 ml virion−1 day−1
μ9 2–5 day−1
μ10 0.45–0.65 day−1
